Genetics testing startup Nucleus Genomics criticized for its embryo product: ‘Makes me so nauseous’

Nucleus Genomics has launched Nucleus Embryo, a controversial new product that claims to test IVF embryos for traits like appearance, IQ, and complex health attributes using polygenic scores, sparking widespread criticism regarding its scientific validity and ethical implications. While Nucleus defends its methodology citing a 2018 paper, experts note that polygenic risk scores are not routinely used due to a lack of guidelines and ongoing research, raising concerns about the accuracy and responsible application of such tests in embryo selection. The company partners with Genomic Prediction, which works with IVF clinics, although Genomic Prediction does not provide intelligence tests.

Analysis

Nucleus Genomics, a privately-held genetic testing startup backed by notable investors including Founders Fund and Alexis Ohanian’s 776, has ignited significant controversy with the launch of its Nucleus Embryo product. This service purports to use polygenic scores to test IVF embryos for a range of traits, including physical appearance, IQ, and susceptibility to complex conditions like anxiety and ADHD, effectively offering parents a tool for embryo selection. This move has drawn considerable criticism, reflected in a negative sentiment score of -0.75 and a critical tone, primarily due to profound ethical concerns regarding 'designer babies' and substantial questions about the scientific validity of applying polygenic risk scores—which the National Human Genome Research Institute states are primarily for assessing relative risk in populations and not yet validated for individual predictive use or clinical guidance—to individual embryo selection for complex traits. While Nucleus defends its methodology, citing a 2018 paper on disease screening, experts emphasize that guidelines for the clinical use of polygenic scores are still lacking. The company is not directly conducting tests via IVF labs but partners with Genomic Prediction, which itself does not offer intelligence tests, and allows parents to voluntarily upload genetic data. This development follows previous criticism of Nucleus's 'Nucleus IQ' product and occurs despite the company securing $14 million in Series A funding, indicating venture capital appetite for its ambitious, albeit contentious, vision in the genetic technology space. The moderate market impact score of 0.45 suggests that while the controversy is intense, its immediate broader market repercussions may be developing or confined to specific sub-sectors like specialized biotech and venture capital.

Key Decisions for Investors

• Investors with direct or indirect exposure to Nucleus Genomics, or those considering investments in early-stage genetic testing firms, should rigorously evaluate the substantial reputational, ethical, and potential regulatory risks highlighted by the overwhelmingly negative and critical reception to Nucleus Embryo.
• The intense debate surrounding Nucleus's application of polygenic scores for embryo selection may precipitate wider public skepticism and regulatory scrutiny of the advanced genetic testing industry, warranting careful monitoring by investors in the broader biotech and healthcare sectors for shifts in public policy and consumer sentiment.
• ESG-focused investors should exercise extreme caution and conduct enhanced due diligence on companies involved in pre-implantation genetic testing for non-medical complex traits, given the significant social and ethical concerns raised by products like Nucleus Embryo.
• Given the company is private, direct public market action is not possible; however, the controversy serves as a case study on the potential for disruptive technologies to face significant societal and scientific headwinds, a factor to consider when evaluating ventures at the intersection of technology, ethics, and healthcare.